– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High Dose vaccine when used in combination in the highly vulnerable 65-85 years old population – Results suggest approach could be used for vaccination against future influenza pandemics such as H5N1 MADISON, Wis., July 12, 2024 (GLOBE NEWSWIRE) -- FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the results of its study comparing the coadministration of intranasal M2SR and the high dose flu shot in an unprecedented study of older adults ages 65-85 years.

–今天在《柳叶刀传染病》杂志上报道的研究结果–研究显示，M2SR和Fluzone高剂量疫苗在65-85岁高度脆弱的人群中联合使用时产生协同免疫反应–结果表明，该方法可用于预防未来的流感大流行，如2024年7月12日在威斯康星州麦迪逊市的H5N1流感大流行（环球通讯社）--FluGen，Inc.，一家临床阶段疫苗公司，改变了传染性呼吸道疾病的疫苗效力，今天宣布了其研究结果，该研究比较了鼻内M2SR和高剂量流感疫苗的共同给药，这是一项前所未有的针对65-85岁老年人的研究。

The findings are reported today in the journal Lancet Infectious Diseases (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00351-7/fulltext). The study evaluated the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine when administered with Sanofi’s Fluzone High Dose inactivated influenza vaccine (IIV).

这些发现今天发表在《柳叶刀传染病》杂志上(https://www.thelancet.com/journals/laninf/article/PIIS1473-3099（24）00351-7/全文）。该研究评估了与赛诺菲的Fluzone高剂量灭活流感疫苗（IIV）一起使用时，FluGen的研究性超季节性，活的，单次复制的鼻内流感（flu）疫苗的安全性，耐受性和免疫反应。

There is a demonstrated unmet need for improved flu vaccine options, as current injectable vaccines primarily generate hemagglutinin (HA) antibodies and have shown only modest efficacy in most flu seasons. Funded by the U.S. Department of Defense (DOD), this study evaluated M2SR and Fluzone High Dose alone, and dosed concomitantly, in healthy adults 65-85 years of age, a population considered highly vulnerable to mortality from flu.

由于目前的可注射疫苗主要产生血凝素（HA）抗体，并且在大多数流感季节仅显示出适度的功效，因此对改进流感疫苗选择的需求尚未得到满足。由美国国防部（DOD）资助，这项研究评估了65-85岁健康成年人（被认为极易死于流感的人群）中单独使用M2SR和Fluzone高剂量，并同时服用。

“Influenza continues to be a major cause of seasonal respiratory epidemics with significant morbidity and mortality, especially in older adults. Current vaccines fall short in three main areas – they don’t last long enough, they don’t protect again.

“流感仍然是季节性呼吸道流行病的主要原因，发病率和死亡率都很高，尤其是在老年人中。目前的疫苗在三个主要方面存在不足-它们持续时间不够长，无法再次保护。